Related Experiment Videos
Mefloquine Prophylaxis and Hearing, Postural Control, and Vestibular Functions
Hessén-Söderman1, Bergenius, Palme
1Department of Audiology and Department of Otolaryngology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.
Journal of Travel Medicine
|June 1, 1995
Summary
Mefloquine (MQ) did not significantly impact balance or the vestibular system in healthy volunteers during a 16-week study. Further flight simulator tests are needed before recommending MQ for pilots.
Area of Science:
- Pharmacology
- Neuroscience
- Travel Medicine
Background:
- Mefloquine (MQ) is a key antimalarial drug.
- Neuropsychiatric side effects, such as dizziness, limit MQ's clinical use.
Purpose of the Study:
- To assess the impact of weekly Mefloquine (MQ) administration on vestibular function and safety in healthy volunteers.
- To evaluate potential correlations between MQ plasma concentrations and adverse effects.
Main Methods:
- Ten healthy volunteers received 250 mg of Mefloquine (MQ) weekly for 16 weeks.
- Evaluations included posturography, nystagmus recording, audiometry, and drug concentration measurements.
- Assessments were conducted at baseline, during treatment, and post-treatment.
Main Results:
- All volunteers completed the study and maintained normal daily activities.
- No significant changes in hearing thresholds or nystagmus were observed.
- Postural sway (sway index) remained within normal limits, with no correlation to MQ plasma concentrations.
Conclusions:
- Weekly Mefloquine (MQ) administration did not appear to affect the vestibular system or hearing in this cohort.
- Mild symptoms were reported, possibly linked to MQ, but did not impede daily function.
- Further vestibular assessments, including flight simulator studies, are recommended for pilots before MQ use.